Tyra Biosciences (TYRA) Projected to Release Earnings on Thursday

Tyra Biosciences (NASDAQ:TYRA) is projected to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect the company to announce earnings of ($0.6499) per share for the quarter. Parties can check the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Tuesday, August 4, 2026 at 4:00 PM ET.

Tyra Biosciences (NASDAQ:TYRA) last released its quarterly earnings data on Tuesday, August 4th. The company reported ($0.69) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.04). On average, analysts expect Tyra Biosciences to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Tyra Biosciences Trading Down 4.1%

Shares of NASDAQ:TYRA opened at $25.18 on Wednesday. The company has a 50 day moving average of $29.89 and a 200 day moving average of $32.63. The stock has a market cap of $1.50 billion, a P/E ratio of -10.49 and a beta of 0.77. Tyra Biosciences has a 12 month low of $9.96 and a 12 month high of $40.65.

Institutional Trading of Tyra Biosciences

A number of hedge funds have recently bought and sold shares of TYRA. Caitong International Asset Management Co. Ltd bought a new position in Tyra Biosciences during the fourth quarter valued at approximately $51,000. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its stake in shares of Tyra Biosciences by 14.5% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 13,182 shares of the company’s stock worth $126,000 after acquiring an additional 1,668 shares in the last quarter. Russell Investments Group Ltd. lifted its holdings in shares of Tyra Biosciences by 27.7% in the 3rd quarter. Russell Investments Group Ltd. now owns 12,741 shares of the company’s stock worth $178,000 after acquiring an additional 2,766 shares during the last quarter. The Manufacturers Life Insurance Company bought a new stake in shares of Tyra Biosciences in the 4th quarter worth approximately $220,000. Finally, VARCOV Co. purchased a new stake in shares of Tyra Biosciences in the 4th quarter valued at $255,000. Institutional investors own 84.14% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have issued reports on the stock. Jefferies Financial Group reiterated a “buy” rating and issued a $42.00 target price on shares of Tyra Biosciences in a research note on Wednesday, August 5th. Guggenheim assumed coverage on shares of Tyra Biosciences in a report on Tuesday, April 14th. They issued a “buy” rating and a $54.00 price target on the stock. Wolfe Research initiated coverage on Tyra Biosciences in a research report on Tuesday, May 19th. They issued a “peer perform” rating on the stock. Bank of America lifted their price objective on Tyra Biosciences from $37.00 to $42.00 and gave the company a “buy” rating in a research note on Wednesday, June 10th. Finally, HC Wainwright restated a “buy” rating and set a $45.00 target price on shares of Tyra Biosciences in a research report on Thursday, May 14th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tyra Biosciences currently has an average rating of “Moderate Buy” and a consensus price target of $46.90.

About Tyra Biosciences

Tyra Biosciences (NASDAQ: TYRA) is a clinical-stage precision oncology company focused on the discovery and development of small-molecule therapies for genetically defined cancers. The company integrates bioinformatics, molecular biology and medicinal chemistry to identify oncogenic drivers and design targeted inhibitors. By leveraging large-scale genomic datasets and functional screening, Tyra Biosciences aims to advance therapies that address patient populations with high unmet medical need.

The company’s pipeline includes multiple programs at various stages of development, each directed against distinct molecular vulnerabilities in cancer cells.